Biosimilars

Latest News

Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA
Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA

April 24th 2024

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

FDA Approves Biosimilar Ustekinumab-aekn for PsO, PsA
FDA Approves Biosimilar Ustekinumab-aekn for PsO, PsA

April 16th 2024

Tocilizumab-aazg Officially Launches in the US for Chronic Autoimmune Diseases
Tocilizumab-aazg Officially Launches in the US for Chronic Autoimmune Diseases

April 16th 2024

Secukinumab and Sandoz Adalimumab Have Similar Outcomes When Treating r-axSPA
Secukinumab and Sandoz Adalimumab Have Similar Outcomes When Treating r-axSpA

April 13th 2024

Elena Christofides, MD | Credit: Endocrinology Associates
Insulin Glargine Biosimilar Demonstrates Bioequivalence to Originator for Type 2 Diabetes

April 13th 2024

Video Interviews
Podcasts
Screenshot from podcast episode.
Latest CME Events & Activities

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!

April 17, 2024

View More

28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

View More

New Combination-Based Approaches to Newly Diagnosed MM: What Do the Data, the Experts, and Patients Say?

19 April 2024

Register Now!

Gene Therapy for Hemophilia B—The Next Step Forward in Disease Management

View More

Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies

View More

(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations

View More

Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis

View More

BURST Expert Illustrations & Commentaries™: A Closer Look at the Role of Complement Inhibitors in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

View More

Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?

View More

27th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

View More

(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease

View More

Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?

View More

(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease

View More

18th Annual Controversies in Modern Eye Care

May 4, 2024

Register Now!

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations

View More

Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

View More

Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy

View More

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis

View More

(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention

View More

Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data

View More

Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference

View More

More News

© 2024 MJH Life Sciences

All rights reserved.